Boston Scientific Announces Schedule For EuroPCR 2012 Sacramento Bee EVOLVE is a prospective, randomized, non-inferiority trial that compares two dose formulations of everolimus on Boston Scientific's SYNERGY Coronary Stent System to the PROMUS Element™ Everolimus-Eluting Coronary Stent System in patients with de novo ... BOSTON SCIENTIFIC CORPORATION : Boston Scientific Announces Schedule For ... |
